Cyclosporine-induced sebaceous hyperplasia in a hematopoetic stem cell transplant patient: Delayed onset of a common adverse event

Reason Wilken, Maxwell A Fung, Vivian Y. Shi, Michelle Y. Cheng, Forum Patel, Hawa Sultani, Emanual Michael Maverakis

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Cyclosporine-induced sebaceous hyperplasia (SH) is a well-documented entity, occurring in up to 30% of renal transplant patients treated with cyclosporine and has also been reported to occur following heart or hematopoetic stem cell transplantation (HCST). Cyclosporine has a stimulatory effect on undifferentiated sebocytes, resulting in the clinical and histologic findings in these patients. Sebaceous hyperplasia most commonly presents as asymptomatic papules over the face, chest, or groin. Herein we describe a case of a 27-year-old man who developed facial sebaceous hyperplasia five months after completing cyclosporine therapy for cutaneous graft versus host disease (GVHD) following HSCT.

Original languageEnglish (US)
Article number4
JournalDermatology Online Journal
Volume22
Issue number1
StatePublished - 2016

Keywords

  • Cyclosporine
  • Sebaceous hyperplasia
  • Transplant

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Cyclosporine-induced sebaceous hyperplasia in a hematopoetic stem cell transplant patient: Delayed onset of a common adverse event'. Together they form a unique fingerprint.

  • Cite this